90 results about "Mania" patented technology

The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-sero-tonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbamaza-pine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam or clonazepam. These compositions are used to treat patients with mood disorders, particularly bipolar disorder with or without psychotic features, mania or mixed episodes. Methods are provided for separate administration of a carbostyril derivative and a mood stabilizer to a patient with a mood disorder.

The present invention is a method for the treatment of mania and / or bipolar disorder comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as herein defined.

The invention relates to the technical field of health management and specifically relates to a chronic disease management system based on exercise intervention, diet intervention and mental intervention. The system provided by the invention comprises an intelligent service platform, portable equipment and a mobile terminal, wherein the portable equipment is used to collect information and transmit the information to the intelligent service platform; the intelligent service platform is used to customize personalized exercise prescriptions, diet prescriptions and mental intervention prescriptions; and the mobile terminal is used to inquire various types of information and prescriptions and assess a user's anxiety, depression, fear, mania, pessimism and happiness degrees by questionnaires. By the invention, a closed-loop health management service can be provided for a client; personalized prescriptions can be issued based on comprehensive evaluation of a patient's health conditions, mental conditions, diet conditions and lifestyles, so that the patient can execute a scheme customized for him / her.

Disclosed are methods, systems, and devices for generating sleep predicators to avoid preventable mental episodes from breaking through, thereby averting an irreversible brain damage to a patient, that may be caused by such future mental episodes. In one embodiment, the present invention is a method comprising: acquiring biomedical data from a patient by using a means of signal acquisition; forming a database of the biomedical records in which the database further comprises a sleep prediction algorithm, psychiatric records, and a statistical engine to compute the data and the psychiatric records using the algorithm; mapping the acquired data in reference to the sleep prediction algorithm; validating the sleep predictors; and providing an output of the sleep predicators to a patient or caretaker. The present invention can be used to treat mania, depression, bipolar disorder, schizophrenia, PTSD, anxiety, and other chronic mental health conditions.

Methods and kits for assessing the susceptibility of a patient to antidepressant-induced mania are described. The method involves testing a sample from a patient for the presence of the s variant of the 5HTTLPR polymorphism in the 5HTT gene. The presence of this s variant indicates that the patient is more susceptible to antidepressant-induced mania.

The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, mania, or bipolar disorder.

The invention relates to methods and compositions for treating schizophrenia or bipolar disorder (in particular, mania) by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an antipsychotic or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In some embodiments, the methods and the compositions are for treating one or more positive and / or negative symptoms, as well as cognitive impairment, associated with schizophrenia or bipolar disorder (in particular, mania).

The invention relates to ascorbic acid lithium and a preparation method thereof. The preparation method of ascorbic acid lithium comprises the following steps: (1) feeding lithium carbonate and ascorbic acid to a water solution to carry out chemical reaction, so as to generate ascorbic acid lithium; (2) continuing to add ethanol to a reaction solution, and separating out ascorbic acid lithium crystal. The prepared ascorbic acid lithium is soluble in water and is organic lithium, can be applied to the field of medicines or foods, for example, can be used as antioxidant preservatives in foods, condiments or beverage, and can also be used as a good drug for treating mania, bipolar affective disorders of alternating attacks of mania and depression, dissociation-affective disorder, cold bronchitis, asthma, pneumonia, hepatitis, liver cancer and high blood pressure.

The present invention provides compounds of the general formula (I)wherein X, n and R1 are as described herein, as well as pharmaceutically acceptable salts and esters thereof, methods for their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are dual modulators of the serotonin 5-HT2a and dopamine D3 receptors, useful in the treatment and / or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.

The present invention relates to methods of treating various CNS disorders, e.g., mania, bipolar disorder and schizophrenia, by administering NMDA receptor antagonists, alone or in combination with dopamine receptor antagonists.

The invention discloses a medicine for treating mental disease. Gentian, aloe, Chinese angelica, goldthread, golden cypress, scutellaria root, cape jasmine fruit, rheum officinale, costustoot, indigo naturalis, musk and chordiazepoxide are mixed uniformly, and crushed into 200-mesh fine powder, and the fine powder is filled into capsules to prepare a capsule preparation. The medicine has the effects of clearing heat and releasing toxin, cooling liver and arresting convulsion, relaxing bowel, and causing resuscitation and restoring consciousness, and is mainly used for treating mania, namely dementia praecox. The medicine has the quick and effective effect of antipsychotic western medicines, also achieves the curing effect of traditional Chinese medicines, does not need to be taken for a long time after the mental disease is cured, reduces harmful side effects on heart, liver, spleen, lung and kidney due to long-term administration of western medicines, and radically solves the problems of mental pressure of psychopaths and troubles for long-term administration of the antipsychotic western medicines. Through clinical curative effect observation, the total effective rate is 88.0 percent.

The present invention provides compounds of the general formula (I)wherein X, n and R1 are as described herein, as well as pharmaceutically acceptable salts and esters thereof, methods for their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are dual modulators of the serotonin 5-HT2a and dopamine D3 receptors, useful in the treatment and / or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.

The invention discloses a Chinese medicinal composition for relieving mind and calming nerve, which is characterized in that: the Chinese medicinal composition is mainly prepared from the following components in part by weight: 7 to 20 parts of arisaema cum bile, 20 to 35 parts of snakegourd fruit, 7 to 20 parts of red orange, 6 to 15 parts of grassleaf sweelflag rhizome, 8 to 18 parts of rhubarb, 16 to 25 parts of figwort root, 6 to 15 parts of golden thread, 20 to 35 parts of Drgon's bones and 6 to 15 parts of Indian buead. The Chinese medicinal composition can recuperate visceral functions of a human body, and balance yin and yang to fulfill the aims of treating both principal and secondary aspect of disease and strengthening the vitality. The Chinese medicinal composition can well control diseases such as paranoid type, insomnia and dreamful sleep, phobic anxiety, melancholy, acoasma, mania and restlessness, neurosis and acute and chronic schizophrenia caused by various reasons, has obvious treatment effect and has the total effective rate of 99.4 percent.

The present invention relates to ether derivatives according to general formula I,and to their pharmaceutically-acceptable salts, which may be used in treating or preventing cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, or psychoses comprising paranoia and delusions.

Lithium is regarded as the gold standard comparator and benchmark treatment for mania. One of the problems associated with Lithium is its narrow therapeutic window. Recent attempts to find new drugs with similar therapeutic activities have yielded new chemical entities. However, these potential new drugs have yet to match the many bioactivities attributable to lithium's efficacy for the treatment of neuropsychiatric diseases. Consequently, an intense effort for re-engineering lithium therapeutics using cocrystallization is currently underway. The evaluation of pharmacokinetics of previously unexplored lithium salts with organic anions (lithium salicylate and lithium lactate) has found that these lithium salts exhibit profoundly different pharmacokinetics compared to the more common FDA approved salt, lithium carbonate, in rats. Remarkably, lithium salicylate produced elevated blood and brain levels of lithium beyond 48 hours post-dose without the sharp peak that contributes to the toxicity problems of current lithium therapeutics.

The present invention provides methods for the diagnosis and treatment of psychiatric disorders. In particular, the present invention provides convergent functional genomics methods for the identification of candidate genes associated with psychiatric disorders such as mania and psychosis, as well as other multi-faceted diseases and syndromes.

The invention discloses an organic acid lithium amino acid salt. An organic acid lithium is one or more of lithium isobutyrate, lithium n-butyrate, lithium lactate, lithium citrate or lithium cholesterol; an amino acid is one of L-proline, valine, lysine or artificially synthesized amino acid; and the organic acid lithium amino acid salt is a salt formed by the organic acid lithium and the amino acid. The invention also discloses a crystal form, a preparation method and application of the salt. The organic acid lithium amino acid salt has a positive curative effect and a prevention effect on repeated attack of mania and depression in bipolar affective disorders, can delay degenerative diseases of a central nervous system to achieve better distribution of the central nervous system, and reduces the clinical dosage of the lithium salt while enhancing the curative effect of the central nervous system diseases, so as to avoid the occurrence of peripheral adverse reaction.

The present invention relates to methods of treating various CNS disorders, e.g., mania, bipolar disorder and schizophrenia, by administering NMDA receptor antagonists, alone or in combination with dopamine receptor antagonists.

The present invention relates to ether derivatives according to general formula I, and to their pharmaceutically-acceptable salts, which may be used in treating or preventing cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, or psychoses comprising paranoia and delusions.

The present invention provides methods of identifying an increased risk of a dopamine dysregulation disorder in a human subject, including identifying increased risk of dementia, Parkinson's disease, Huntington's, epilepsy, mania, attention deficit disorder, anxiety, dyslexia, schizophrenia, depression, obsessive-compulsive disorders, alcoholism, obesity, addiction disorders, pathological gambling, attention deficit hyperactivity disorder, bipolar disorder, Tourette syndrome, substance dependence, sub stance abuse, substance overdose, and substance-related death.

The invention discloses a safe treatment chair device for psychopaths. The safe treatment chair device for the psychopaths comprises a base, wherein two armrests are separately arranged on two sides of a seat portion; a backrest is arranged at the rear of the seat portion; at least two upper limb binding belts are arranged on the backrest; a headrest is arranged above the backrest; a sound box isarranged in the headrest; a head cover is arranged on the top of the backrest; a colored hypnosis lamp is arranged on the inner wall of the head cover; at least two leg binding belts are arranged on aleg bracket; a foot support is arranged on the bottom of the leg bracket; and two foot grooves for placing feet are formed in the leg bracket close to the foot support. When a psychopath is examined,relaxed music can be played through the sound box arranged in the headrest to assist in stabilizing the emotion of the psychopath, the psychopath can be fixed on the backrest through the upper limb binding belts, the legs of the psychopath are fixed on the leg bracket through the leg binding belts, the psychopath is prevented from mania during examining to affect detection, and working intensityof medical staff is relieved.

The present invention relates to N-[(4-hydroxypiperidine-4- Base) methyl] pyridin-2 (1H)-one derivatives, their stereoisomers, their pharmaceutically acceptable salts and their solvates, and their preparation methods, and their use in the prevention or treatment of 5-HT system dysfunction Related central nervous system diseases such as depression, anxiety, cognitive deficits, mania, schizophrenia, pain, etc., or used as a tool drug to study 5-HT function and its 5-HT dysfunction related diseases, and pharmaceutical compositions containing these compounds. Each substituent in formula I is as described in the specification.

The invention discloses a preparation process of organic acid lithium-L-proline salt, and relates to the field of synthesis and preparation of organic lithium salt micromolecular medicines. The lithium isobutyrate-L-proline salt is prepared by adopting a single solvent method and a mixed solvent method so as to achieve the purposes of development and clinical application of new organic lithium salt. The organic acid lithium-L-proline salt has positive curative effects and prevention effects on recurrent mania and depression in bipolar affective disorder, has a unique suicide risk prevention effect, can effectively relieve anxiety, depression and other emotional abnormalities, can delay central nervous system degenerative changes, and changes the in vivo distribution defects of existing inorganic lithium salt. In addition, the purpose of modifying the physical and chemical properties of a drug can be achieved by adopting a pharmaceutical eutectic or salifying technology without changingthe public valence structure of drug molecules, the clinical dosage of the lithium salt is reduced while the curative effect of central nervous system diseases is enhanced, and the occurrence of peripheral adverse reactions is avoided.

The invention discloses application of an adenosine compound WS070133 shown as formula I in preparation of products for prevention or treatment of stress disorders. The stress disorders and related diseases include acute stress disorder, posttraumatic stress disorder, adjustment disorder and phobia, anxiety, mania, bipolar disorder and other diseases. Oral administration of WS070133 on posttraumatic stress disorder model animals shows that the adenosine compound has the effects of lowering animal stress level, reducing fear, anxiety like symptoms and learning and memory impairment. Study also shows that WS070133 can lower the corticosterone level and excitatory amino acid content, reduce apoptosis of neurons and has a regulation effect on related protein molecules. WS070133 has the advantages of low toxicity, no dependence, metabolic and addiction, quick metabolic clearance and no residual effect, etc., thus havaing good application and development prospects. (formula I).

The present invention relates to muscarinic receptor modulators, specifically, 7-oxo-2-azabicyclo[2.2.1]heptanes of formula (I) which are useful for the treatment of various diseases and conditions, for example, Alzheimer's disease, glaucoma, psychosis, particularly schizophrenia or schizophreniform conditions, mania, pain, bipolar disorder, depression, sleeping disorders, epilepsy, gastrointestinal motility disorders, urinary incontinence, and cognition enhancement.

A liquid pharmaceutical composition of a GABA analog comprising at least one polyhydric alcohol containing 2 to 6 carbon atoms having a pH of about 5.5 to about 7.0 and additionally a two-component liquid pharmaceutical composition comprising a first component comprising a powder mixture comprising a GABA analog and a solid polyhydric alcohol, and a second component comprising a liquid base are described, as well as methods to prepare the compositions and a method for treating cerebral diseases, including epilepsy, faintness attacks, hypokinesia and cranial traumas, neurodegenerative disorders, depression, mania and bipolar disorders, anxiety, panic, inflammation, renal colic, insomnia, gastrointestinal damage, incontinence, pain, including neuropathic pain, muscular pain, skeletal pain, and migraine using a therapeutically effective amount of the pharmaceutical compositions.

The invention discloses an intelligent nursing device for psychiatric nursing, and mainly relates to the field of psychiatric restraint tools. The nursing device comprises a restraint ring, a rotatingring, a restraint rod and an air bag, wherein the restraint ring and the rotating ring are rotationally connected on a circumferential end face; sliding blocks which are in sliding fit in the axial direction of the restraint ring are arranged on the inner wall of the restraint ring; first ball joint seats are arranged on the sliding blocks; second ball joint seats with the same number as the sliding blocks are arrayed on the inner wall of the rotating ring in the circumferential direction; the two ends of the restraint rod are matched with the first ball joint seats and the second ball jointseats respectively; the air bag is fixed to an inner ring of the restraint ring; inflation and deflation of the air bag are achieved through a medical air source; a pulse detection piece is fixed to the air bag; the pulse detection piece is in signal connection with a stepping motor; and the stepping motor is triggered to be started by setting a lower limit threshold value of the heart rate. The nursing device has the beneficial effects that the locking is timely, constraint is fast, the four-limb behavior of a patient in a mania state is fast responded and constrained, limitation is reliableand safe, and the injury to the patient is greatly reduced.